Abstract
AbstractRadiolabelled drug lead candidate leukocyte function‐associated antigen 1 antagonist [14C]spyrocyclic hydantoin: 5‐(((5S,9R)‐9‐(4‐[14C]‐cyanophenyl)‐3‐(3,5‐dichlorophenyl)‐1‐methyl‐2,4‐dioxo‐1,3,7‐triazaspiro[4.4]nonan‐7‐yl)methyl)thiophene‐3‐carboxylic acid, 12, was conveniently prepared in three radiochemical steps from (5S,9R)‐tert‐butyl 9‐(4‐bromophenyl)‐3‐(3,5‐dichlorophenyl)‐1‐methyl‐2,4‐dioxo‐1,3,7‐triazaspiro[4.4]nonane‐7‐carboxylate 9. The radiochemical yield of 12 was 28.5% from the resolved bromide 9. The preparation of the racemic spyrocyclic hydantoin 3 was obtained via a [3+2]dipolar cycloaddition reaction between 2 and N‐benzyl‐N‐(methoxymethyl)trimethylsilylmethylamine. The introduction of [14C] cyanide was completed via a palladium (0) catalyzed reaction by the addition of Zn(14CN)2 to aryl bromide 9. The radiochemical and chiral purities of 12 determined by high‐performance liquid chromatography were 98.7 and 99.7%, respectively. The specific activity of 12 was 87.5 µCi/mg (48.6 mCi/mmol). Copyright © 2009 John Wiley & Sons, Ltd.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Labelled Compounds and Radiopharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
